Pathophysiology - The Nicotine Hijack
- Primary Target: Nicotine is a potent agonist at nicotinic acetylcholine receptors (nAChRs) in the central nervous system.
- Reward Pathway Activation:
- Binds to α4β2 nAChRs in the Ventral Tegmental Area (VTA).
- Triggers dopamine release in the Nucleus Accumbens (NAc) and prefrontal cortex.
- This activation of the mesolimbic reward system produces pleasure and powerfully reinforces tobacco use.
- Neuroadaptation & Withdrawal:
- Chronic use upregulates nAChRs, leading to tolerance.
- Abrupt cessation causes a hypo-dopaminergic state, resulting in withdrawal symptoms like irritability, craving, and anxiety.

⭐ Varenicline (Chantix) works as a partial agonist at the α4β2 nAChR, reducing cravings and blunting the rewarding effects of nicotine if the patient relapses.
Clinical Features - Smoke & Mirrors
- Core Features (DSM-5):
- Using larger amounts or for longer than intended.
- Persistent desire or unsuccessful efforts to cut down.
- Significant time spent obtaining, using, or recovering from tobacco.
- Craving: A powerful, compulsive urge to use.
- Continued use despite physical or psychological problems (e.g., COPD, anxiety).
- Physical Signs:
- "Smoker's cough," dyspnea, wheezing.
- Yellow/brown stains on teeth and fingers.
- Premature skin wrinkling.

- Withdrawal Syndrome:
- Onset within 24 hours of cessation; peaks at 1-3 days.
- 📌 CRAVED: Craving, Restlessness, Anxiety/Anger, Vexation, Eating more (weight gain), Depressed mood/Difficulty concentrating.
⭐ The number of cigarettes smoked per day and the time to the first cigarette after waking are key indicators of nicotine dependence severity.
Management - The Quitting Blueprint
-
Counseling & Behavioral Support (The 5 A's)
- Ask: Systematically identify all tobacco users at every visit.
- Advise: Strongly urge all tobacco users to quit.
- Assess: Determine willingness to make a quit attempt.
- Assist: Aid the patient in quitting (pharmacotherapy, counseling).
- Arrange: Schedule follow-up.
-
Pharmacotherapy: First-Line Options
- Varenicline: Partial nicotinic receptor agonist. Most effective single agent.
- Bupropion: Antidepressant (NDRI). CI: Seizure d/o, eating disorders.
- Nicotine Replacement Therapy (NRT):
- Long-acting: Patch
- Short-acting: Gum, lozenge, inhaler, nasal spray.
- Combination (patch + short-acting) is superior to monotherapy.
⭐ Varenicline's partial agonism reduces withdrawal cravings while simultaneously blocking nicotine from binding, which blunts the rewarding effect of smoking.
- Quitting Algorithm
- Nicotine withdrawal is characterized by irritability, anxiety, and intense cravings, peaking within 1-2 days.
- First-line treatments include varenicline (a partial nicotinic agonist) and bupropion (an NDRI antidepressant).
- Varenicline can increase the risk of cardiovascular events in susceptible individuals.
- Bupropion is contraindicated in patients with seizure or eating disorders (e.g., bulimia).
- Combining behavioral counseling with pharmacotherapy is the most effective treatment approach.
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more